- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02162953
Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.
Development of Induced Pluripotent Stem Cells From Patients With Best Disease and Other Inherited Retinal Degenerative Diseases.
Background: Autosomal recessive bestrophinopathy (ARB) is one of 5 blinding eye diseases caused by mutations in the gene BEST1. These diseases, collectively termed "bestrophinopathies" include ARB, Best vitelliform macular dystrophy (BVMD), adult-onset vitelliform dystrophy (AVMD), autosomal dominant vitreoretinalchoroidopathy (ADVIRC) and retinitis pigmentosa (RP) .
Objective: To collect DNA/RNA and skin samples from individuals with ARB or other diseases due to mutations in the gene BEST1. These models will be used to identify and test therapeutic approaches to treating these diseases.
Design: Study involves a one time donation of a skin punch biopsy and whole blood. Once the skin biopsy is obtained, skin fibroblasts will be isolated, which will be reprogrammed into iPSCs. RPE cells will be derived from the iPSCs
Study Overview
Status
Detailed Description
The PI on this proposal has been studying BEST1 and the protein encoded (Best1) since its discovery in 1998. Best1 is an integral membrane protein that in the eye is expressed only by retinal pigment epithelial (RPE) cells where it is localized to the basolateral plasma membrane.
Methods: Once a subject has been identified as a potential candidate, a study coordinator will meet with the subject, to discuss the study prior to sample collection. The study coordinator will review the consent form with the subject and spend as much time as necessary answering any questions. Once the subject has signed the consent form, study procedures will begin.
Following the consent process, a skin sample will be obtained from subjects using a (4mm) dermal punch biopsy method. This will be accomplished in a single visit to the Regenerative Medicine Consult Service or other approved clinical examination room. A suture may need to be placed following this skin biopsy. A health care provider (either at Mayo Clinic or a local health care provider's office) can remove the stitches, or the subject can remove them with a provided disposable suture removal kit.
Subjects will also be asked to undergo venipuncture; all subjects will be asked to have the venipuncture and have the option to refuse. 10ml of blood will be collected for RNA and DNA extraction.
Once the skin biopsy is obtained,skin fibroblasts will be isolated, which will be reprogrammed into iPSCs. RPE cells will be derived from the iPSCs.
Remuneration: If subjects make a special trip only for the research procedures, they may be reimbursed for travel expenses including: airfare, mileage, parking, and hotel. In order to receive reimbursement, they must provide a copy of the original receipts for those expenses. Reimbursement will not exceed $1000.00.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient must have been diagnosed on the basis of genotyping with a bestrophinopathy.
- Patient must be willing to provide a skin biopsy from which we will generate iPSCs.
- For pediatric patients, parents must be willing to donate skin biopsies as well.
Exclusion Criteria:
- Children under the age of 5
- Patients exhibiting secondary ophthalmic disorders that are not typically associated with the bestrophinopathies may be excluded.
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of iPS cells successfully differentiated into RPE cells
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alan D. Marmorstein, Ph.D., Mayo Clinic
- Principal Investigator: Raymond Iezzi, M.D., Mayo Clinic
- Principal Investigator: Sophie J. Bakri, M.D., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-008089
- U01EY030547 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Disease
-
LKC Technologies, Inc.Unknown
-
University Hospital, Strasbourg, FranceNot yet recruitingInherited Retinal DiseaseFrance
-
Retinagenix HoldingsWithdrawnRetinal DisorderUnited States
-
Janssen Research & Development, LLCRecruitingInherited Retinal DiseasesUnited States, Korea, Republic of, Canada, Spain, Denmark, Germany, France, Italy, Israel, Austria, United Kingdom
-
University Hospital Inselspital, BerneCompletedRetinal DiseaseSwitzerland
-
Topcon Medical Systems, Inc.CompletedNormal Eyes | Eyes With Glaucoma | Eyes With Retinal DiseaseUnited States
-
Gangnam Severance HospitalCompletedInherited Retinal Dystrophy Primarily Involving Sensory Retina | Inherited Retinal Dystrophy Primarily Involving Retinal Pigment EpitheliumKorea, Republic of
-
University Hospital Inselspital, BerneUniversity of Bern; Haag-Streit AGNot yet recruitingRetinal DiseaseSwitzerland
-
Hopital FochRecruiting